Trade representatives for Canada and Mexico met last week over the ratification and implementation of the United States–Mexico–Canada Agreement (USMCA), and press reports say that the Trump administration is considering acceding to Democrats’ demands to reduce patent protections for reference biologics in order to get the pact through Congress.
Trade representatives for Canada and Mexico met last week over the ratification and implementation of the United States—Mexico–Canada Agreement (USMCA), and press reports say that the Trump administration is considering acceding to Democrats’ demands to reduce patent protections for reference biologics in order to get the pact through Congress.
The USMCA was signed by the 3 countries on November 30, 2018, ostensibly as a replacement for the original North American Free Trade Agreement (NAFTA), just weeks after Democrats took control of the House of Representatives.
The biosimilars industry has been working since earlier this year to convince legislators to join them in opposing a pharmaceutical intellectual property provision in the USMCA. Currently, the provision would give 10 years of marketing exclusivity for biologic drugs.
Under US law, the period of exclusivity is 12 years; Democratic leaders in the House of Representatives want the time reduced to fewer than 10 years, possibly to 8 years.
Canada’s current exclusivity period for biologics is 8 and Mexico’s is 5, meaning that US biosimilar exports would have to wait longer if the additional timeframe in the USMCA passes.
The Association for Accessible Medicines has said that the USCMA will hinder generic and biosimilar competition, particularly as the manufacturing process for biosimilars becomes more efficient.
Mexico’s trade negotiator, Jesús Seade, spoke optimistically about the possibility of a deal on Twitter after the meeting with Canada, and was also said to have met with the US trade representative.
In the United States, the regulatory exclusivity provisions of the Biologics Price Competition and Innovation Act (BPCIA) already provide for a longer exclusivity period than required by the USMCA; the BPCIA provides 4 years of data exclusivity and 12 years of marketing exclusivity for reference biologic products
Representative Jim Himes, D-Connecticut, told The Wall Street Journal this week that a deal before Christmas is possible. But Senator Chuck Grassley, R-Iowa, chairman of the Senate Finance Committee, said that if a deal is not reached this week, he does not see how a 2019 ratification is possible.
Innovator biotechnology firms and pharmaceutical industry groups, such as the Biotechnology Innovation Organization, known as BIO, and the Pharmaceutical Research and Manufacturers of America, known as PhRMA, approve of the intellectual property language currently in the agreement.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.